知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

116 records (took 0.039 seconds)

    Vaginal speculum for photodynamic therapy and method of using the same
    11.
    发明授权
    Vaginal speculum for photodynamic therapy and method of using the same 失效
    阴道窥器用于光动力疗法及其使用方法

    公开(公告)号：US5458595A

    公开(公告)日：1995-10-17

    申请号：US168553

    申请日：1993-12-16

    Applicant: Yona Tadir ,  Michael W. Berns ,  Brad J. Monk ,  Glen Profeta ,  Bruce J. Tromberg

    Inventor： Yona Tadir ,  Michael W. Berns ,  Brad J. Monk ,  Glen Profeta ,  Bruce J. Tromberg

    IPC: A61B1/32 ,  A61B17/22 ,  A61B17/42 ,  A61B18/22 ,  A61B19/00 ,  A61N5/06 ,  A61B17/32

    CPC classification number: A61B1/32 ,  A61B1/07 ,  A61B17/42 ,  A61B18/22 ,  A61N5/0601 ,  A61N5/062 ,  A61B2017/22087 ,  A61B2090/062

    Abstract: An improved vaginal speculum for photodynamic therapy of intraepithelial tissue and in particular vaginal, cervical and vulvar neoplasia utilizes a precisely and accurately positionable optic fiber through which a predetermined dose of light in the range of 620 to 700 nanometers is delivered over a controlled area which has been previously treated with photodynamic therapeutic substances. In particular, the neoplastic area has been treated with hematoporphyrin derivatives and other photosensitizers which are selectively taken into the cancerous tissue. Exposure to the appropriate wavelength laser light photoactivates the absorbed hematoporphyrins causing the release of singlet oxygen which internally oxidizes and ultimately causes cell death. The fiber optic tip from which the laser light is transmitted is precisely positioned within the body cavity at a predetermined distance from the intraepithelial neoplasia in order to obtain the appropriate spot size and location to minimize damage to healthy tissue and maximize damage to the selectively impregnated cancerous tissue.

    Abstract translation: 用于上皮内组织，特别是阴道，宫颈和外阴肿瘤的光动力治疗的改进的阴道窥器利用精确和准确的可定位的光纤，通过该光纤将620-700纳米范围内的预定剂量的光量传送到具有 以前用光动力治疗物质治疗。 特别地，肿瘤区域已被血卟啉衍生物和其它选择性摄入癌组织的光敏剂中治疗。 暴露于合适的波长激光光激活吸收的血卟啉，导致释放内在氧化并最终导致细胞死亡的单线态氧。 将激光从其传播的光纤尖端精确地定位在距离上皮内瘤变形预定距离的体腔内，以便获得适当的斑点大小和位置，以最小化对健康组织的损伤并最大限度地损害选择性浸润的癌性 组织。

    Apparatus and method of use for a photosensitizer enhanced fluorescence based biopsy needle
    12.
    发明授权
    Apparatus and method of use for a photosensitizer enhanced fluorescence based biopsy needle 失效
    用于光敏剂的装置和方法增强基于荧光的活检针

    公开(公告)号：US5318023A

    公开(公告)日：1994-06-07

    申请号：US679766

    申请日：1991-04-03

    Applicant: Sandor G. Vari ,  Theodore Papazoglou ,  Warren S. Grundfest

    Inventor： Sandor G. Vari ,  Theodore Papazoglou ,  Warren S. Grundfest

    IPC: A61B5/00 ,  A61B10/00 ,  A61B10/02 ,  A61B17/22 ,  A61B18/20 ,  A61B18/22 ,  A61B19/00

    CPC classification number: A61B10/0233 ,  A61B18/22 ,  A61B5/0059 ,  A61B5/415 ,  A61B5/418 ,  A61B2017/22087 ,  A61B2090/062

    Abstract: A method and apparatus is disclosed for the instant intraoperative detection and biopsy of metastatic cancer using fluorescence spectroscopy. A photosensitizing agent selectively retained by cancerous tissue is administered prior to surgery. A fiberoptic probe integrated with a biopsy device illuminates the examined tissue and causes fluorescence which is recorded by a spectrograph and plotted as a spectral curve. The intensity ratio (S1/S2) for the fluorescence from the photosensitizing agent (S1) and autofluorescence (S2) for the examined tissue is compared with the intensity ratio at the same wavelengths for primary tumor and normal tissue. Tissue that displays an intensity ratio different from that of normal tissue can immediately be analyzed for the depth of tumor involvement and then excised for histological examination using the biopsy device.

    Abstract translation: 公开了使用荧光光谱法进行的转移性癌症的即时术中检测和活检的方法和装置。 在手术前给予由癌组织选择性保留的光敏剂。 与活检装置集成的光纤探针照亮被检查的组织并引起荧光，其由光谱仪记录并绘制为光谱曲线。 将来自光敏剂（S1）的荧光和检测组织的自发荧光（S2）的强度比（S1 / S2）与原发肿瘤和正常组织的相同波长的强度比进行比较。 显示与正常组织不同的强度比的组织可以立即分析肿瘤深度，然后用活检装置进行组织学检查。

    Laser delivery system
    13.
    发明授权
    Laser delivery system 失效
    激光输送系统

    公开(公告)号：US5169395A

    公开(公告)日：1992-12-08

    申请号：US691696

    申请日：1991-04-26

    Applicant: Hugh L. Narciso, Jr.

    Inventor： Hugh L. Narciso, Jr.

    IPC: A61B17/22 ,  A61B18/22 ,  A61F7/12 ,  A61M29/02 ,  A61N5/06

    CPC classification number: A61N5/062 ,  A61N5/0601 ,  A61B2017/22038 ,  A61B2017/22087 ,  A61B2018/2261 ,  A61F7/12 ,  A61M25/104

    Abstract: A system is described for the delivery of light to, and/or the receiving of light from, a target located on the wall of a tortuous tube such as a blood vessel. The delivery system is generally useful for laterally delivering and receiving light for the detection and photodynamic therapy of target tissue and is particularly useful for the treatment of atherosclerosis. When certain biocompatible photoreactive molecules such as hematoporphyrin or the like are injected into a patient the molecules are selectively taken up by target tissue such as tumors or atheromatous plaque. Subsequent illumination of the target tissue activates the photoreactive molecules causing fluorescence emission from, and destruction of, the host target tissue. The preferred embodiments comprise a hollow optical waveguide terminating in a supple diffuser tip which may be inserted over an intravascular flexible guide wire. The optical delivery catheter is advanced along the guidewire until the diffuser tip reaches the target tissue. Light of a wavelength suitable to activate previously injected photoreactive molecules is delivered to the target causing selective cell lysis and/or target tissue destruction. The disclosed system is also capable of delivering laser energy for simultaneous hyperthermic generation and photodynamic therapy.

    Abstract translation: 描述了一种系统，用于从位于诸如血管的弯曲管的壁上的靶递送光和/或接收光。 递送系统通常用于侧向递送和接收用于靶组织的检测和光动力治疗的光，并且对于治疗动脉粥样硬化特别有用。 当将某些生物相容的光反应性分子如血卟啉等注入患者时，分子被靶组织如肿瘤或动脉粥样硬化斑块选择性地摄取。 靶组织的随后照射激活导致主体靶组织的荧光发射和破坏的光反应分子。 优选实施例包括端接在柔性扩散器末端中的中空光波导，其可插入血管内柔性引导线上。 光学输送导管沿着导丝前进，直到扩散器尖端到达靶组织。 适用于激活先前注射的光反应性分子的波长的光被传递到靶，导致选择性细胞裂解和/或靶组织破坏。 所公开的系统还能够提供用于同时发热和光动力疗法的激光能量。

    Intracorporeal Medicaments for High Energy Phototherapeutic Treatment of Disease
    15.
    发明申请
    Intracorporeal Medicaments for High Energy Phototherapeutic Treatment of Disease 审中-公开
    体内高能量光疗治疗疾病的药物

    公开(公告)号：US20100076246A1

    公开(公告)日：2010-03-25

    申请号：US12543653

    申请日：2009-08-19

    Applicant: H. Craig Dees ,  Timothy C. Scott ,  Eric A. Wachter ,  Walter G. Fisher ,  John Smolik

    Inventor： H. Craig Dees ,  Timothy C. Scott ,  Eric A. Wachter ,  Walter G. Fisher ,  John Smolik

    IPC: A61N5/10 ,  A61K31/352 ,  A61P35/04

    CPC classification number: A61K31/352 ,  A61B2017/22062 ,  A61B2017/22087 ,  A61K9/0019 ,  A61K41/0038 ,  A61N5/0601 ,  A61N5/062 ,  A61N5/10 ,  A61N2005/1098 ,  C07D311/82

    Abstract: New intracorporeal radiodense medicaments and certain medical uses and methods for use of such high energy phototherapeutic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. The halogenated xanthenes constitute a family of potent radiosensitizers that become photoactivated upon irradiation of the treatment site with ionizing radiation. In embodiments of the present invention, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection. In another embodiment, such medicaments are produced in various formulations including liquid, semisolid, solid or aerosol delivery vehicles.

    Abstract translation: 描述了新的体内放射碘化物药物和用于治疗人或动物组织的这种高能光疗药物的某些医学用途和方法，其中这种药物的主要活性成分是卤代呫吨或卤化呫吨衍生物。 卤化呫吨构成了一种有效的放射增敏剂，其在用电离辐射照射治疗部位时变得光活化。 在本发明的实施方案中，这些药物用于治疗影响皮肤和相关器官，口腔和消化道及相关器官，泌尿生殖道和相关器官，呼吸道及相关器官的各种病症， 循环系统和相关器官，头颈部，内分泌和淋巴系统及相关器官，各种其他组织，例如结缔组织和手术期间暴露的各种组织表面，以及表现出微生物或寄生虫感染的各种组织。 在另一个实施方案中，这些药物是以包括液体，半固体，固体或气溶胶输送载体在内的各种制剂生产的。

    Medicaments for chemotherapeutic treatment of disease
    16.
    发明授权
    Medicaments for chemotherapeutic treatment of disease 失效
    化疗药物治疗疾病

    公开(公告)号：US07648695B2

    公开(公告)日：2010-01-19

    申请号：US09900355

    申请日：2001-07-06

    Applicant: H. Craig Dees ,  Timothy C. Scott

    Inventor： H. Craig Dees ,  Timothy C. Scott

    IPC: A61K51/00 ,  A61M36/14 ,  G01N33/00

    CPC classification number: A61K41/0057 ,  A61B2017/22062 ,  A61B2017/22087 ,  A61F7/00 ,  A61K9/0014 ,  A61K9/0019 ,  A61K31/352 ,  A61K41/0071 ,  A61K47/10 ,  A61K47/12 ,  A61K47/20 ,  A61N5/0601 ,  A61N5/062 ,  C07D311/82 ,  Y02A50/473 ,  Y10T436/193333

    Abstract: New chemotherapeutic medicaments and certain medical uses and methods for use of such chemotherapeutic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. Preferably, the halogenated xanthene is Rose Bengal or a functional derivative of Rose Bengal. The halogenated xanthenes constitute a family of useful chemotherapeutic agents that afford selective, persistent accumulation in certain tissues. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection. In another preferred embodiment, such medicaments are produced in various formulations useful for intracorporeal or topical administration, including in liquid, semisolid, solid or aerosol delivery vehicles.

    Abstract translation: 描述了新的化学治疗药物和用于治疗人或动物组织中的这种化学治疗药物的某些医疗用途和方法，其中这种药物的主要活性成分是卤化呫吨或卤代呫吨衍生物。 优选地，卤代呫吨是玫瑰红或玫瑰红的功能衍生物。 卤代呫吨构成一系列有用的化学治疗剂，其在某些组织中提供选择性的，持续的积累。 在优选的实施方案中，这些药物用于治疗影响皮肤和相关器官，口腔和消化道及相关器官，泌尿生殖道和相关器官，呼吸道及相关器官，循环系统 内脏和淋巴系统及相关器官，各种其他组织，如结缔组织和手术期间暴露的各种组织表面，以及表现出微生物或寄生虫感染的各种组织。 在另一个优选的实施方案中，这些药物可用于体内或局部给药的各种制剂，包括在液体，半固体，固体或气溶胶输送载体中。

Patent Agency Ranking